TECH.NASDAQBio-techne CORP

Form 4: Bio-Techne Director Exercises Stock Options

Sentiment:

Insider Transaction Report

📋All filings for Bio-techne CORP
🔒Login to Follow

Bio-Techne Director John L. Higgins exercised 5,040 stock options at $21.84 per share, increasing his direct common stock holdings to 65,236 shares.

Summary

  • John L. Higgins, a Director of Bio-Techne Corp (TECH), exercised 5,040 stock options.
  • The exercise price for these options was $21.84 per share.
  • Following this transaction, Higgins directly holds 65,236 shares of Bio-Techne Common Stock.
  • The exercised options were originally granted on October 29, 2016, and were set to expire on October 28, 2025.
  • Higgins retains additional stock options with various exercise prices and expiration dates, including 3,511 options granted on October 24, 2024, which vest on the earlier of October 24, 2025, or the date of Bio-Techne's 2025 annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The exercise of stock options by a director is generally a positive signal, indicating the insider perceives value in exercising options at a specific price, likely below the current market price, and increasing their direct stake in the company. It suggests confidence in the company's future prospects.

Positives

  • An insider, John L. Higgins, exercised stock options, indicating confidence in the company's future performance, as the exercise price ($21.84) is likely below the current market price (implied by the exercise).
  • The transaction increases the director's direct ownership in the company, aligning his interests further with shareholders.

Future Outlook

The filing indicates future vesting for some stock options held by the director, specifically 3,511 options granted on October 24, 2024, which will vest on the earlier of October 24, 2025, or the date of Bio-Techne's 2025 annual meeting of shareholders.

Industry Context

This filing is a routine insider transaction and does not provide information for broader industry trend analysis. Bio-Techne operates in the life sciences and diagnostics industry.

Related Party Transactions

  • The exercise of stock options by a director is a related party transaction, as it involves an insider acquiring company securities.

Stakeholder Impact

  • Shareholders: The transaction increases the director's alignment with shareholder interests through increased direct equity ownership. It can be viewed as a positive signal of insider confidence.

Next Steps

  • Vesting of 3,511 stock options (exercise price $68.37) on the earlier of October 24, 2025, or the date of Bio-Techne's 2025 annual meeting of shareholders.

Key Dates

DateDescription
10/29/2016Grant date of the stock option exercised on 08/07/2025.
10/26/2017Grant date of remaining stock options with exercise price $25.30.
10/25/2018Grant date of remaining stock options with exercise price $31.26.
10/24/2019Grant date of remaining stock options with exercise price $44.96.
10/24/2020Grant date of remaining stock options with exercise price $50.41.
10/28/2021Grant date of remaining stock options with exercise price $63.92.
10/27/2022Grant date of remaining stock options with exercise price $128.81.
10/26/2023Grant date of remaining stock options with exercise price $73.94.
10/24/2024Grant date of remaining stock options with exercise price $61.51 and $68.37.
08/07/2025Date of stock option exercise transaction.
10/24/2025One-year anniversary of grant date for options vesting on earlier of this date or 2025 annual meeting.
10/28/2025Expiration date of the stock option exercised on 08/07/2025.
2025Expected year of Bio-Techne's annual meeting of shareholders, which is a potential vesting date for certain options.
10/26/2026Expiration date of remaining stock options with exercise price $25.30.
10/26/2027Expiration date of remaining stock options with exercise price $31.26.
10/25/2028Expiration date of remaining stock options with exercise price $44.96.
10/24/2029Expiration date of remaining stock options with exercise price $50.41.
10/29/2030Expiration date of remaining stock options with exercise price $63.92.
10/28/2031Expiration date of remaining stock options with exercise price $128.81.
10/27/2032Expiration date of remaining stock options with exercise price $73.94.
10/26/2033Expiration date of remaining stock options with exercise price $61.51.
10/24/2034Expiration date of remaining stock options with exercise price $68.37.
08/11/2025Date the Form 4 was signed by Andrew Nick as Attorney-in-Fact.

Recommendation

hold

The filing details a routine insider stock option exercise, which is generally a positive signal of confidence from a director. However, a single insider transaction, while indicative, is typically not sufficient on its own to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance, suggesting continued monitoring of the company's broader financial performance and strategic developments.

Keywords

Bio-Techne, TECH, SEC Form 4, Insider Trading, Stock Options, Director, Equity, Beneficial Ownership, John L. Higgins

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.